A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Inclusion Criteria: * Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF). * Subject has Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1. * Subject has a new clinical or pathologic diagnosis of resectable HPV+ or HPV- SCCHN of the oral cavity, pharynx, or larynx * Macroscopic complete resection of the primary tumor must be planned and subjects should have no medical contraindication to surgery. * Subject consents to and has tumor accessible for tumor biopsy pre-treatment. * Subjects must have acceptable hematopoietic, liver, renal, and coagulation function as assessed by laboratory tests. Exclusion Criteria: * Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study * Subject has unresectable or inoperable tumors * Subject has primary tumors of the sinuses, paranasal sinuses, or nasopharynx, or unknown primary tumors * Subject has evidence of distant metastasis * Subject is a pregnant or nursing female. * Subject has active or uncontrolled infection including known HIV infection or known chronic hepatitis B or C. * Subject has active autoimmune disease. * Subject has clinically significant ophthalmologic disease.